Ascentage Pharma Advances 2022 RSU Scheme with Share Purchase

Story Highlights
Ascentage Pharma Advances 2022 RSU Scheme with Share Purchase

Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.

Ascentage Pharma Group International announced the purchase of 50,000 shares by a trustee for its 2022 Restricted Share Unit (RSU) Scheme, representing approximately 0.014% of the total issued shares. This purchase is part of the company’s ongoing efforts to satisfy RSUs upon exercise, reflecting its commitment to employee incentive programs and potentially enhancing shareholder value.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company based in Suzhou, China, focusing on developing therapies for cancers, hepatitis B, and age-related diseases. The company is incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange.

YTD Price Performance: -5.39%

Average Trading Volume: 3,736,216

Technical Sentiment Signal: Sell

Current Market Cap: HK$14.85B

For detailed information about 6855 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App